Spyre Therapeutics Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)2.32 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $89.93Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $7.9B Enterprise Value $7.8B Shares Outstanding 88.2M diluted Next Earnings Date31 Dec 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and rational combinations to redefine the standard of care in inflammatory bowel disease (IBD) and rheumatic diseases. By utilizing half-life extension technology (YTE backbone) and high-concentration formulations, Spyre's candidates (SPY001, SPY002, SPY003) target quarterly or twice-annual subcutaneous dosing, offering a highly competitive profile compared to existing therapies. Recent positive Phase 2 SKYLINE Part A readouts for SPY001 (anti-a4b7) and SPY002 (anti-TL1A) validate the platform's potential for best-in-class efficacy and convenience. Backed by a robust pro forma cash position of $1.18 billion, Spyre has a secure runway into the second half of 2029, significantly de-risking its clinical execution. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$97.00 Mean target$124.71 High · most bullish analyst$140.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $97.0010% Upcoming clinical readouts for SPY003 or the combination therapies fail to show differentiation or reveal safety concerns. Intense competition from established players (e.g., AbbVie, Roche) limits market potential, and high R&D burn rates accelerate the need for dilutive capital raises. Base CaseCentral scenario $124.7160% Matches the consensus meanSpyre successfully completes Phase 2 monotherapy readouts with competitive efficacy and safety profiles. The company advances its combination therapies into pivotal trials, maintaining its cash runway into 2029 and securing partnerships or favorable financing terms. Bull CaseUpside scenario $140.0030% All three monotherapies (SPY001, SPY002, SPY003) demonstrate best-in-class efficacy and safety in Phase 2 trials, and the pairwise combinations (SPY120, SPY130, SPY230) show synergistic, paradigm-shifting efficacy in Part B. Dosing convenience (Q3M/Q6M) drives rapid market adoption, capturing significant market share from established biologics. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |